Downloading...
Download

Biomed

TG Therapeutics forming 3rd baseIs a company that develops and commercializes novel treatments for B-cell diseases The stock initiated a bull trend at the end of 2023 after a breakaway gap and has gained +90% during 2024 and gave 2 opportunities to buy on breakouts Now is forming a 3rd base and may give another opportunity to enter, all this while relative to its sector AMEX:XLV is making new highs According to IBD is not among the industry leaders, but it has a 96 Relative Strength Rating against the SP:SPX
NASDAQ:TGTXLong
by dpuleo19
EARS update: You made money if you were patient!We're looking at a $3.08 long term POC, with around $5 POC if you include the crazy volume day it went up to ~$10 closed around $8. Bulls seem to have identified a support here and it's getting frothy off of no news! I think it's more and more investors catching wind of the Covid nasal spray preventive, along with the domination Auris has in ear, nose and throat diseases. I still have lofty long term goals, but will update with more DD soon on possible competitors.
ELong
by Drip_Drop
WAVE.V -- Bottoming Out Undervalued Pharma/COVID-19 PlayThe most attractive part of WAVE.V is share structure: 54M total float with 41M shares held by insiders / escrowed, leaving about 13M shares free trading. The company owns a portfolio of generic oncology drugs from which it generates over $300K of quarterly revenue. $1M in cash on hand. Based on last financials, they are $83K away from generating positive cash flow and recent developments suggest they will get there sooner rather than later: -- Received grant to develop a rapid COVID-19 saliva based test in partnership with the University of Manitoba -- Received authorization from several EU countries to expand sales of their generic oncology drugs -- Expecting FDA authorization in Q4 2020 At below $10M mkt cap and in the absence of any cheap paper overhang, I feel that this is a tremendous opportunity. Compare it to something like THRM.V which is developing a similar saliva-based COVID-19 test, has next to nothing in revenues, a ton of cheap paper, 3x the float and 3x the market cap, and you realize that current valuation makes no sense. Chart suggests the stock is reversing from short term downtrend after finding bottom at .15. A doji, followed by green candle on increased volume and EMA 20 crossing above EMA 50 providing additional support at .16. Today was a pullback on lower volume that resulted in a higher low. I used it as an opportunity to pad my position. Next catalysts that could propel sp to significantly higher levels are updates on the oncology drug sales in Europe, rapid COVID-19 test development progress and FDA approval of oncology drugs for sale/marketing in the US.
TSXV:WAVELong
by agstockpicks
BPTH - Good News in Dec = Enormous ProfitsBPTH, the ticker to the company Bio Path Holdings is currently trending down. This ticker has been a poor performer for the entire year with small time periods where day traders may make an easy 20-60 percent. Bio Path may seem like a decent day trading target where it follows the downward trending line and tends to bounce up a few days after coming into contact with it. If this continues, one can easily make short term gains and find value in this, but it will make much more sense to wait. Bio Path will be releasing news on its number one drug, Prexigebersen for Acute Myeloid Leukemia (AML). This drug with good data has the potential of making Bio Path a multi billion dollar company. As you can see last year, Bio Path jumped from a startling ~$1 per share to ~$70 per share with one good news release. It is not easy to find these opportunities very often, that's why timing is the key. Bio Medical companies tend to slowly decrease in value or, "bleed" waiting for positive news from the company. This is due to the companies being unprofitable and often seek financing deals creating stock dilution. The good news is what makes the stock relatively value because of the opportunity for day traders to capitalize on large percentage gains with a simple news release, but at the same time, you could also lose a large amount if it were negative. Bio Path will release news on Prexigebersen this December and if you don't know enough about it, I recommend you do a little research on your own. Any investment in this company is indeed speculation. Investing with small positions is the proper strategy with bio-med. Cheers, AC
BLong
by RayleWoodInvestments
FOMX - Foamix Pharma Reversal Pattern FormedOn October 18th, 2019, the FDA approved Amzeeq, otherwise known as FMX101 for the Israel based pharmaceutical company, Foamix. Amzeeq happens to be the first and only topical monocyline treatment to be used on acne patients. In anticipation of approval for this new product, shares of FOMX rallied from $2.53 per share on 10/08/2019 all the way up to highs around $3.63 per share. As it turns out, the anticipation for the approval is now correcting lower to what seemed to be overbought conditions in anticipation. FOMX 101 is expected to be entering into the market early next year with the hopes of being on shelves for January 2020. This new topical treatment will be entering the dermatology market which happens to be worth several billion dollars. This is very good news for a company that has been anticipating FDA approval for several years, these are make or break moments for new companies. If you look at the chart above, I posted what seems to be a hammer which I am waiting for the end of the day for confirmation. If this pattern holds, this may be a reversal pattern to hop into FOMX to join the reversal towards December price targets between $3-$6 dollars. Watch to see if the hammer pattern holds, then watch to see if the reversal in confirmed. If we see a reversal, we may be looking towards short terms gains of 25% and higher. Option markets are pricing in a high volume of $4 and $5 strike price calls for december. Cheers, AC
FLong
by RayleWoodInvestments
MRK needs to find support - what to look forHey everyone, Moving away from the typical crypto posts today. We are checking out MRK. This stock has seen some hefty losses in the past few days, pushing the RSI into a oversold area The increasing bear volume has not been supportive, and the price is breaking past the .382 fib level. The stock is looking to find support, but the last few days have not shown any. Before entering into this long position, we need to see some consolidation on price and bullish movement. Increasing bear volume after a week of losses is also not supportive of increasing price levels. The RSI will need to cool off towards the 40-45 range before we can see some bullish movement. After consolidation, wait for price to retreat to a newly made bullish fib level, signaling a new trend. Once a new high is made, it opens the stock up to a head and shoulders pattern, pointing south again. We would need to see bullish divergence either from volume or from the RSI to bring price higher after this. As is, we are in a bear movement that could pose a falling knife until proper support forms. What do you think? Where could we support form? -Block
NYSE:MRK
by block21e8
Potential pennant breakout on $MXC over coming days.Initial move of around 100% has had some time to consolidate and soak away remaining supply which has been thinning considerably since the first move. Recently the green bars have been finding much less supply therefore the possibility of a significant move is increasing. If the topside break occurs then 12.0c would be the target This medical cannabis company have signed several decent sales/distribution agreements recently and have an upcoming catalyst in the form of a definitive multi $M Australian pharmaceutical distributor
MLong
by Michaeljob
1
Quantum Dots Are Making a Wall Street Wonder, What's It About?It's about Quantum Materials Corp. (OTCQB:QTMM) a nanotechnology company that can make copious amounts of quantum dots. If you never heard of a quantum dot you are not alone. The average person doesn't understand, know if you can see them with the naked eye, how they are used or what they even are. Quantum dots are man made crystals 10,000 times smaller than a human hair, thus smaller than human cells. Their special electrical conductivity properties have generated a new class of semiconductor. These unique nanocrystals, also known as nanoparticles, are creating quite a stir in several industries because the technology applications are across a broad spectrum and you may remember the growth of companies like Intel, Samsung and Texas Instruments that were making semiconductors. Quantum Materials Corp. makes Quantum Dots which are the next generation of semiconductors. You can't say now that you didn't have a chance to look into what a Quantum Dot company is about with return potentials like Dell, Microsoft, Apple and Amazon. I suggest you investigate further Quantum Materials Corp - ticker QTMM and then if you decide not to invest at least follow the company developments. You can always change your mind later, just don't watch another life time opportunity pass you by. Life is too short waiting for the next one to come by. Remember by the time feature magazines and newspapers like Barron's, Forbes or The Wall Street Journal start covering breaking technology companies like Quantum Materials Corp. , the most potential for maximizing profit has already slipped past you and out your wallet! Good luck, health and prosperity to you. Bill Leigh Invest wisely!
QLong
by ih8aloss